Meegan A Walker1, Birgitte Hoier2, Philip J Walker3, Karl Schulze4, Jens Bangsbo5, Ylva Hellsten6, Christopher D Askew7. 1. School of Health and Sport Sciences, University of the Sunshine Coast, Sippy Downs, Queensland, Australia. Electronic address: mwalker@usc.edu.au. 2. Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark. Electronic address: bhoier@nexs.ku.dk. 3. School of Medicine, Royal Brisbane and Women's Hospital, University of Queensland, Herston, Queensland, Australia. 4. Sunshine Vascular Surgery and Imaging, Buderim, Queensland, Australia. 5. Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark. Electronic address: jbangsbo@nexs.ku.dk. 6. Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark. Electronic address: yhellsten@nexs.ku.dk. 7. School of Health and Sport Sciences, University of the Sunshine Coast, Sippy Downs, Queensland, Australia. Electronic address: caskew@usc.edu.au.
Abstract
BACKGROUND: Peripheral arterial disease (PAD) is characterised by impaired leg blood flow, which contributes to claudication and reduced exercise capacity. This study investigated to what extent vasoactive enzymes might contribute to altered blood flow in PAD (Fontaine stage II). METHODS: We compared femoral artery blood flow during reactive hyperaemia, leg-extension exercise and passive leg movement, and determined the level of vasoactive enzymes in skeletal muscle samples from the vastus lateralis in PAD (n = 10, 68.5 ± 6.5 years) and healthy controls (CON, n = 9, 62.1 ± 12.3 years). Leg blood flow was measured with Doppler ultrasound and muscle protein levels of phosphorylated endothelial nitric oxide synthase, NADPH oxidase, cyclooxygenase 1 and 2, thromboxane synthase, and prostacyclin synthase were determined. RESULTS: Leg blood flow during the initial 90 s of passive leg movement (242 ± 33 vs 441 ± 75 ml min(-1), P = 0.03) and during reactive hyperaemia (423 ± 100 vs 1255 ± 175 ml min(-1), P = 0.002) was lower in PAD than CON, whereas no significant difference was observed for leg blood flow during exercise (1490 ± 250 vs 1887 ± 349 ml min(-1), P = 0.37). PAD had higher NADPH oxidase than CON (1.04 ± 0.19 vs 0.50 ± 0.06 AU, P = 0.02), with no differences for other enzymes. Leg blood flow during exercise was correlated with prostacyclin synthase (P = 0.001). CONCLUSION: Elevated NADPH oxidase indicates that oxidative stress may be a primary cause of low nitric oxide availability and impaired blood flow in PAD.
BACKGROUND:Peripheral arterial disease (PAD) is characterised by impaired leg blood flow, which contributes to claudication and reduced exercise capacity. This study investigated to what extent vasoactive enzymes might contribute to altered blood flow in PAD (Fontaine stage II). METHODS: We compared femoral artery blood flow during reactive hyperaemia, leg-extension exercise and passive leg movement, and determined the level of vasoactive enzymes in skeletal muscle samples from the vastus lateralis in PAD (n = 10, 68.5 ± 6.5 years) and healthy controls (CON, n = 9, 62.1 ± 12.3 years). Leg blood flow was measured with Doppler ultrasound and muscle protein levels of phosphorylated endothelial nitric oxide synthase, NADPH oxidase, cyclooxygenase 1 and 2, thromboxane synthase, and prostacyclin synthase were determined. RESULTS:Leg blood flow during the initial 90 s of passive leg movement (242 ± 33 vs 441 ± 75 ml min(-1), P = 0.03) and during reactive hyperaemia (423 ± 100 vs 1255 ± 175 ml min(-1), P = 0.002) was lower in PAD than CON, whereas no significant difference was observed for leg blood flow during exercise (1490 ± 250 vs 1887 ± 349 ml min(-1), P = 0.37). PAD had higher NADPH oxidase than CON (1.04 ± 0.19 vs 0.50 ± 0.06 AU, P = 0.02), with no differences for other enzymes. Leg blood flow during exercise was correlated with prostacyclin synthase (P = 0.001). CONCLUSION: Elevated NADPH oxidase indicates that oxidative stress may be a primary cause of low nitric oxide availability and impaired blood flow in PAD.
Authors: Alec L E Butenas; Tyler D Hopkins; Korynne S Rollins; Kennedy P Felice; Steven W Copp Journal: Am J Physiol Heart Circ Physiol Date: 2019-08-30 Impact factor: 4.733
Authors: Elissa K Hoopes; Felicia R Berube; Michele N D'Agata; Freda Patterson; William B Farquhar; David G Edwards; Melissa A H Witman Journal: Sleep Date: 2021-02-12 Impact factor: 5.849
Authors: J Carter Luck; Amanda J Miller; Faisal Aziz; John F Radtka; David N Proctor; Urs A Leuenberger; Lawrence I Sinoway; Matthew D Muller Journal: J Appl Physiol (1985) Date: 2017-04-06
Authors: M Wojewoda; K Przyborowski; B Sitek; A Zakrzewska; L Mateuszuk; J A Zoladz; S Chlopicki Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2016-12-03 Impact factor: 3.000
Authors: Jacqueline K Limberg; Darren P Casey; Joel D Trinity; Wayne T Nicholson; D Walter Wray; Michael E Tschakovsky; Daniel J Green; Ylva Hellsten; Paul J Fadel; Michael J Joyner; Jaume Padilla Journal: Am J Physiol Heart Circ Physiol Date: 2019-12-30 Impact factor: 4.733
Authors: Corey R Hart; Gwenael Layec; Joel D Trinity; Yann Le Fur; Jayson R Gifford; Heather L Clifton; Russell S Richardson Journal: Am J Physiol Heart Circ Physiol Date: 2018-06-22 Impact factor: 4.733
Authors: Joel D Trinity; Oh Sung Kwon; Ryan M Broxterman; Jayson R Gifford; Andrew C Kithas; Jay R Hydren; Catherine L Jarrett; Katherine L Shields; Angela V Bisconti; Soung Hun Park; Jesse C Craig; Ashley D Nelson; David E Morgan; Jacob E Jessop; Amber D Bledsoe; Russell S Richardson Journal: Am J Physiol Heart Circ Physiol Date: 2020-12-11 Impact factor: 4.733